NDAORALTABLET
Approved
Jun 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
BIDIL (hydralazine hydrochloride and isosorbide dinitrate) by R-Pharm US is established. Approved for heart failure, to prolong time to hospitalization for heart failure, to improve patient-reported functional status and 1 more indications. First approved in 2005.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIDIL is an oral fixed-dose combination of hydralazine hydrochloride and isosorbide dinitrate approved for heart failure in 2005. Isosorbide dinitrate is a vasodilator that releases nitric oxide to relax vascular smooth muscle, while hydralazine selectively dilates arterial smooth muscle and may mitigate nitrate tolerance. The combination is indicated to prolong time to hospitalization and improve functional status in heart failure patients.
$0.002BPart D
LOE ApproachingDeclining
Minimal commercial activity with only $2M in Part D spending and 2,985 claims signals a niche, mature product with limited team expansion opportunities.
Mechanism of Action
established. Isosorbide dinitrate is a vasodilator affecting both arteries and veins. Its dilator properties result from the release of nitric oxide and the subsequent activation of guanylyl cyclase, and ultimate relaxation of vascular smooth muscle. Several well-controlled clinical trials have…
Pharmacologic Class:
Nitrate Vasodilator
Indications (3)
Worked on BIDIL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.